Perspective Comprehensive Prescribing Facts OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or after 3 or maybe more strains of systemic therapy that includ